Opebacan ophthalmic

Drug Profile

Opebacan ophthalmic

Alternative Names: BPI 21 ophthalmic; I-PREX; rBPI 21 ophthalmic; Recombinant bactericidal permeability increasing protein 21 ophthalmic

Latest Information Update: 03 Aug 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator XOMA
  • Class Antibacterials; Recombinant proteins
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Ocular inflammation; Ophthalmic infections

Most Recent Events

  • 15 Jul 2005 XOMA has terminated its license agreement with Zephyr Sciences for ophthalmic opebacan
  • 10 Nov 2004 Opebacan ophthalmic has been licensed to Zephyr Sciences worldwide
  • 24 Nov 2000 Allergan has returned all rights to I-PREX™ to XOMA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top